Clifton Mining Company Inc. (OTC : CFTN) – ABL Animal Study Released

ALPINE, UT, Jan. 18 /PRNewswire-FirstCall/ — American Biotech Labs (ABL), a private company (Clifton Mining Company owns over 24% of ABL) has just received the results of a completed animal study from an international partner in Mumbai, India. In the animal model study identified as number four, the bacteria infected animals showed a 66% survivability rate when given the ABL silver supplement in comparison to a 16% survivability rate in animals where the product was not used (the control group).

   THE STUDY   ———   

The study was completed by VIRIDIS BioPharma, a biopharma company that has partnered with ABL on a number of projects. The bacteria used in the study was a pathogenic strain of Pseudomonas aeruginosa, a very deadly and problematic form of bacteria. The experimental animals were first given one dose of the ABL silver supplement (0.2 mg/kg) 24 hours before being infected with the bacteria, as a prophylactic dose (preventative dose). The animals were then injected intra-peritoneal with a large dose of bacteria (100,000,000 + bacteria count). The bacteria was then given four to five hours of untreated time to start infecting the animals. After the four to five hour start time, the animals were given the ABL silver supplement by gastric intubation at a level of 0.2 mg/kg, 32 ppm, every 8 hours until the animals either died or recovered. The animals were observed for 72 hours to see if they would live or die. Sixty-six percent of the supplement treated animals survived in the study showing normal eating, drinking, and grooming behavior. Only sixteen percent of the non-treated animals (control group) survived the bacterial infection.

While the exact mechanism of action of the ABL silver supplement is not known at this time, the authors of the study suggest that the product may be working as an immuno-modulator, meaning that the product may be stimulating the natural ability of the immune system to fight against the infection.

The results of this study are released for scientific background information only and are not intended to represent what the product may or may not do in human usage.

Clifton trades on the U.S. OTC: (CFTN).

Note: Any statements released by Clifton Mining Company that are forward looking are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Editors and investors are cautioned that forward looking statements invoke risk and uncertainties that may affect the company’s business prospects and performance.

Clifton Mining Company

CONTACT: Dr. Ken Friedman, President, (303) 642-0659; Keith Moeller,Vice President, (801) 756-1414; or see our website at http://www.cliftonmining.com/